Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

被引：16
|
作者：
Lee, Hun Ju
Choi, Michael Y.
Siddiqi, Tanya
Barrientos, Jacqueline Claudia
Wierda, William G.
Isufi, Iris
Tuscano, Joseph M.
Lamanna, Nicole
Subbiah, Suki
Koff, Jean Louise
Leslie, Lori Ann
Goldenberg, Alec
Chung, Gina G.
Breitmeyer, James Bradley
Hsu, Frank J.
Wang, Michael
Jamieson, Catriona
Kipps, Thomas J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[3] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
[4] Northwell Hlth, Feinstein Inst Med Res, Karches Ctr Oncol Res, Manhasset, NY USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Yale Univ, Sch Med, Hematol, New Haven, CT USA
[7] Univ Calif Davis, Davis, CA 95616 USA
[8] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[9] LSU Hlth Sci Ctr, New Orleans, LA USA
[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[11] John Theurer Canc Ctr, Lymphoma Res Div, Hackensack, NJ USA
[12] Manhattan Hem Onc Associates, New York, NY USA
[13] Christ Hosp, Lindner Ctr Res & Educ, Cincinnati, OH 45219 USA
[14] Oncternal Therapeut Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.7556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7556
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)
    Lee, Hun Ju
    Choi, Michael
    Siddiqi, Tanya
    Barrientos, Jacqueline
    Wierda, William G.
    Isufi, Iris
    Tuscano, Joseph
    Lamanna, Nicole
    Subbiah, Suki
    Koff, Jean L.
    Leslie, Lori A.
    Goldenberg, Alec
    Chung, Gina G.
    Breitmeyer, James B.
    Yazji, Salim
    Wang, Yao
    Wang, Michael
    Jamieson, Catriona
    Kipps, Thomas J.
    BLOOD, 2021, 138
  • [2] Phase 1/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 13 - 14
  • [3] Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
    Lee, Hun Ju
    Choi, Michael Y.
    Siddiqi, Tanya
    Rhodes, Joanna Meehan
    Wierda, William G.
    Isufi, Iris
    Tuscano, Joseph M.
    Lamanna, Nicole
    Subbiah, Suki
    Koff, Jean Louise
    Leslie, Lori Ann
    Goldenberg, Alec
    Chung, Gina G.
    Yazji, Salim
    Wang, Yao
    Breitmeyer, James Bradley
    Wang, Michael
    Jamieson, Catriona
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
    Lee, Hun Ju
    Choi, Michael Y.
    Siddiqi, Tanya
    Wierda, William G.
    Barrientos, Jacqueline C.
    Lamanna, Nicole
    Goldenberg, Alec
    Isufi, Iris
    Tuscano, Joseph
    Subbiah, Suki
    Koff, Jean L.
    Leslie, Lori A.
    Chung, Gina G.
    Weihe, Elizabeth K.
    Ianopulos, Xen
    Breitmeyer, James B.
    Hsu, Frank J.
    Wang, Michael
    Jamieson, Catriona
    Kipps, Thomas J.
    BLOOD, 2020, 136
  • [5] Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)
    Lee, Hun Ju
    Choi, Michael Y.
    Siddiqi, Tanya
    Rhodes, Joanna M.
    Wierda, William G.
    Isufi, Iris
    Tuscano, Joseph M.
    Lamanna, Nicole
    Subbiah, Suki
    Koff, Jean L.
    Leslie, Lori
    Goldenberg, Alec
    Chung, Gina G.
    Breitmeyer, James B.
    Yazji, Salim
    Wang, Michael
    Jamieson, Catriona
    Kipps, Thomas J.
    BLOOD, 2022, 140
  • [6] Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
    Lee, Hun Ju
    Choi, Michael Y.
    Siddiqi, Tanya
    Wierda, William G.
    Claudia Barrientos, Jacqueline
    Lamanna, Nicole
    Goldenberg, Alec
    Isufi, Iris
    Tuscano, Joseph M.
    Subbiah, Suki
    Weihe, Elizabeth Kristine
    Ianopulos, Xen
    Breitmeyer, James Bradley
    Hsu, Frank J.
    Wang, Michael
    Jamieson, Catriona Hm
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] IBRUTINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA
    McDermott, J.
    Jimeno, A.
    DRUGS OF TODAY, 2014, 50 (04) : 291 - 300
  • [8] Ibrutinib in Patients (Pts) with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) with Relapsed Disease Post Allogeneic Stem Cell Transplantation (alloSCT)
    Khouri, Issa F.
    Jabbour, Elias
    Saliba, Rima M.
    Ledesma, Celina
    Burger, Jan A.
    O'Brien, Susan
    Gulbis, Alison M.
    BLOOD, 2015, 126 (23)
  • [9] Clinical Activity of Cirmtuzumab, an Anti-ROR1 Antibody, in Combination With Ibrutinib: Interim Results of a Phase Ib/II Study in Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 13 - 13
  • [10] Clinical Activity of Cirmtuzumab, an Anti-ROR1 Antibody, in Combination With Ibrutinib: Interim Results of a Phase Ib/II Study in Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 6 - 8
12345